source
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…
- Novartis shares tumble as three late-stage drug candidates fail trialsNovartis' stock fell more than 13% this week after news that three of its late-stage programs did not meet expectations, pulling down other pharma stocks in the market. The antibody‑oligonucleotid…